uploads/2017/07/Part-4-Recommendations-1.png

Wall Street’s Views and Recommendations for Praxair

By

Updated

Analyst recommendations for Praxair

As of July 5, 2017, there were 20 brokerage firms actively tracking Praxair (PX) stock. About 45.0% of those analysts have recommended a “buy” for the stock, 50.0% have recommended a “hold,” and 5.0% have recommended a “sell.”

Analyst consensus is a 12-month target price of $138.47 for Praxair, implying a potential return of 4.1% from the closing price of $132.66 as of July 5, 2017.

Article continues below advertisement

Why analysts are recommending a ‘hold’

Praxair’s better-than-expected 1Q17 earnings and the upward revision of its EPS (earnings per share) for fiscal 2017 most likely influenced analysts to recommend a “hold” on the stock. In addition, its merger with Linde AG is expected to benefit shareholders, with expected synergies of $1.2 billion in cost savings. That could be another reason investors are recommending a “hold” for the stock.

Target prices of individual brokerage firms

  • JPMorgan (JPM) recommended a target price for Praxair of $156, which implies a potential return of 17.6% compared to the July 5, 2017, closing price of $132.66.
  • Raymond James Financial (RJF) has recommended a target price of $144 for Praxair, implying a potential return of 8.5% over the closing price of $132.66 as of July 5, 2017.
  • Deutsche Bank (DB) also raised its target price for Praxair to $142, implying a potential return of 7.0% over the closing price of $132.66 as of July 5, 2017.
  • HSBC (HSBC) has rated Praxair a “hold” with a target price of $127. However, the stock is already trading 4.5% above that recommended target price.

You can indirectly hold Praxair by investing in the ProShares Ultra Basic Materials (UYM), which has invested 4.2% of its portfolio in Praxair.

Advertisement

More From Market Realist